Advertisement

A randomized pilot study on the effectiveness and side-effect profiles of two doses of digoxin as fetocide when administered intraamniotically or intrafetally prior to second-trimester surgical abortion

      Abstract

      Background

      Digoxin is commonly used to facilitate second-trimester surgical abortion despite limited data regarding its safety and effectiveness for this indication. We conducted a pilot study to determine the incidence of side effects after digoxin administration and whether effectiveness can be improved with variations in dose and technique.

      Study design

      Fifty-two women presenting for elective termination of pregnancy between 18 and 24 weeks' gestation were randomized to one of four digoxin treatment groups: 1.0 mg intraamniotic (1.0 IA), 1.0 mg intrafetal (1.0 IF), 1.5 mg intraamniotic (1.5 IA) or 1.5 mg intrafetal (1.5 IF). Ultrasound was used to assess for the presence of fetal cardiac activity prior to the abortion procedure. Data on the presence and severity of pain, nausea and other potential side effects were collected before digoxin injection, immediately following digoxin injection and on the day after digoxin injection.

      Results

      Digoxin effectively induced fetal death in 87% of women. The failure rate did not vary by route of administration (IA or IF) and was not lowered by increasing the dose from 1.0 to 1.5 mg. IF injections induced fetal death more rapidly than IA injections. Digoxin administration did not result in increased pain or nausea.

      Conclusions

      IA or IF injection of digoxin is safe and effective for inducing fetal death prior to second-trimester surgical abortion. Doses greater than 1.0 mg may not be necessary.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jackson R.A.
        • Teplin V.L.
        • Drey E.A.
        • Thomas L.J.
        • Darney P.
        Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial.
        Obstet Gynecol. 2001; 97: 471-476
        • Molaei M.
        • Jones H.G.
        • Weiselberg T.
        • McManama M.
        • Bassell J.
        • Westhoff C.
        Effectiveness and safety of digoxin to induce fetal death prior to second-trimester abortion.
        Contraception. 2008; 77: 223-225
        • Paul M.
        • Lichtenberg E.S.
        • Borgatta L.
        • Grimes D.A.
        • Stubblefield P.G.
        • Creinin M.D.
        Management of unintended and abnormal pregnancy comprehensive abortion care.
        Wiley-Blackwell, Oxford, UK2009
      1. Partial-Birth Abortion Ban Act of 2003, enrolled as agreed to or passed by both House and Senate from the US Government Printing Office, Washington, DC.

        • Drey E.A.
        • Thomas L.J.
        • Benowitz N.L.
        • Goldschlager N.
        • Darney P.D.
        Safety of intraamniotic digoxin administration before late second-trimester abortion by dilation and evacuation.
        Am J Obstet Gynecol. 2000; 185: 1063-1066
        • Hern W.M.
        • Zen C.
        • Ferguson K.
        • Hart V.
        • Haseman M.V.
        Outpatient abortion for fetal anomaly and fetal death from 15���34 menstrual weeks' gestation: techniques and clinical management.
        Obstet Gynecol. 1993; 81: 301-306
        • Hern W.
        Laminaria, induced fetal death and misoprostol in late abortion.
        Int J Gynaecol Obstet. 2001; 75: 279-286
        • Taylor J.S.
        • Ellis G.R.
        Racial differences in response to drug treatment: implications for pharmacotherapy of heart failure.
        Am J Cardiovasc Drugs. 2002; 2: 389-399
        • Mathew J.
        • Wittes J.
        • McSherry F.
        • et al.
        • Digitalis Investigation Group
        Racial differences in outcome and treatment effect in congestive heart failure.
        Am Heart J. 2005; 150: 968-976

      Linked Article